Recurrent Gastric Cancer Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent / Gastric carcinoma recurrent

IndicationStatusPhase
DBCOND0028800 (Recurrent Gastric Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00061932Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachTreatment
NCT00084604Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaTreatment
NCT00084617Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction CarcinomaTreatment
NCT00991952Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By SurgeryTreatment